- About Journal Carcinogenesis & Mutagenesis Case Reports
- In Press
- Editorial board
- Current Issue
- Submit Manuscript
- Publication Charges
Journal Carcinogenesis & Mutagenesis Case Reports
All the work at Science Repository is licensed under a Creative Commons Attribution 4.0 International License. Authors at Science Repository retain copyright to their work and allow others to copy, distribute, transmit, and adapt their work, provided proper attribution is given.
For submission authors can directly submit manuscript to email@example.com
Manuscripts number will be provided to the corresponding author within 72 hours for the respective manuscript submitted.
- 14 day review process with international peer-review standards
- Timeline of processing from Submission to Publication is 30 days
- Manuscript will be published within 7 days of acceptance
In Press Volume 1, Issue 1
Will be updated soon
- Rwik Sen
- Stefano Bonacci
- Silvia Cantara
- Sabry Attia
- Mahara Angélica Valverde Ramírez
- Zhou B Peter
- Yu-Fei Jiao
- Vincenzo Desiderio
- Vicki Plaks
- Vicente Notario
- Sophia Ran
- Siva K Gandhapudi
- Shyamal Dilip Desai
- Sharad Singhal
- Selva Baltan
- Sanjay K Srivastava
- Sandip Kumar Mishra
- Qingrong Huang, PhD
- Barbara Jarzab
- Mazin Al Salihi
- Porunelloor A Mathew
- Paul Tchounwou
- Noula D Shembade
- Rachana Garg
- Mukesh Verma
- Mong-Hong Lee
- MM Misro
- MJ Molina-Garrido
- Mfon Samuel Cyrus-David
- Marighoula Varla Leftherioti
- Matthew E Witek
- Matteo A Russo
- Masayoshi Yamaguchi
- Kar Muthumani
- Kailash C Chadha, PhD
- Junpeng Qi
- Jon S. Cardinal
- Jing Gung Chung, PhD
- Jessica Partin
- Janaina Fernandes
- Jagat R Kanwar
- Gloria I Sanchez
- Gary Guishan Xiao
- Maria Angelica Cortez
- EI Han
- Zhichao Fan
- Nicholas van Panhuys
- Thomas G Bird
- Smita S. Chandran
- Ann Richmond
- Rajendra Karki
- Qiang Nai
- Peiwen Fei
- Mukesh K. Pandey
- Behjatolah Monzavi-Karbassi
- Katsuhiko Matsui
- Carlos E Marroquin
- Mallika Tewari
- Guangan Hu
- Binfeng Lu
- Leandro Bueno Bergantin
- Hank Schmidt MD PHD
- Dongfeng Wu
- Demir Akin
- Dae Joon Kim
- Chulso Moon
- Christian Rolfo
- Charles Kumar Thodeti
- Ardeshir Hakam, MD, MBA
- Anil Wali
- Andras Falus
- Ajay Rana
- Shuo Chen
- Mohammad Hasanzadeh
- Ved Pal Singh
- Rameshwar NK Bamezai
- Carina Alexandra Fernandes Ladeira
- Afshin Amini
- Michael Eckart
- Khandelwal Sharad Ratan
- Meena Upadhayaya
- Richard J Simpson
- Gregory S Yochum
- Muhammad Akram
- Rahul S. Shinde
Department of Craniofacial Biology
University of Colorado Anschutz Medical Campus
Obtained Ph.D. in Molecular Biology, Microbiology, and Biochemistry from Southern Illinois University. Research involves understanding how craniofacial development and defects are regulated by epigenetics and mitochondrial metabolism. Also studying cardiac defects and epigenetics. I have studied transcription and DNA repair. Expert in various microbial and vertebrate model systems.
GlaxoSmithKline Vaccines srl
Dr. Stefano Bonacci is currently working as Research Scientist in GlaxoSmithKline, Preclinical Evidence & Bioassays Function, Siena, Italy. He received his PhD from Siena in 2008. His research interests include: high-throughput automation of lab processes, robotics applied to protocols, vaccine development, protein-protein interactions, protein chip technology, enzyme characterization.
Department of Medical Surgical and Neurological Sciences
University of Siena
Dr. Cantara is currently a researcher at the Department of Medical, Surgical and Neurological Sciences, Unit of Endocrinology, University of Siena, Italy. She received a Ph.D. in Molecular Medicine from the University of Siena, Italy, in 2004, studying molecular aspects of angiogenesis. She completed post-doctoral research at the Department of Molecular Biology (University of Siena), investigating the role of the circulating progenitor endothelial cells in neo-vascularization and angiogenesis. After, she moved to the Department of Medical, Surgical, and Neurological Sciences and completed a project on the in vitro and in vivo modulation of oncogene(s) implicated in thyroid cancer. Dr. Cantara became researcher of the University of Siena, Italy in 2010 and actively participated to pilot studies determining the role of molecular analysis in refining the diagnosis of thyroid cancer. Dr. Cantara’s current research program is focused on the genetic screening of thyroid tumor specimens, genetic alterations responsible for the familial form of thyroid cancer and genetic factors implicated in other endocrine disorders and obesity.
Department of Pharmacology Toxicology
King Saud University
Riyadh, Saudi Arabia
Dr. Attia is a Professor of Pharmacology and Toxicology at College of Pharmacy at Al-Azhar University, Cairo, Egypt. Dr Attia now works full time as a Professor at College of Pharmacy, King Saud University, Saudi Arabia. He received his Ph.D. in Genetics at Technical University of Munich, Germany in 2004. Dr. Attia also has worked as a postdoctoral fellow at GSF-Institute of Experimental Genetics and Helmholtz Zentrum München-Genome Analysis Center, Germany. This period of research was concerned with developing new methodologies for drug screening, mutagens detection and prevention. During his scientific career, Dr. Attia has developed an expertise in several advanced techniques and research protocols related to molecular cytogenetic. Since 2001, Dr. Attia authored and co-authored over 140 peer-reviewed articles and book chapters, and supervised and co-supervised number of graduate and postgraduate students. He is a reviewer and editor for many reputable international journals. He has received grants from federal and local agencies and from various foundations. He has been an invited speaker in many national and international conferences and he is the recipient of numerous national and international awards and honours for his contribution to the scientific research.
Mahara Angélica Valverde Ramírez
Researcher at Instituto de Investigaciones Biomédicas
Genomic Medicine and Environmental Toxicology
Universidad Nacional Autónoma de México
Currently, my lines of research are focused on the study of DNA damage and repair capacity in different biological systems to understand the acquisition of genetic instability in carcinogenesis and disease. Studies of biomonitoring the cytotoxic and genotoxic effects induced by mixtures of xenobiotics. My main experience is in the Comet assay, being a pioneer in the assay using epithelial biomatrices.
Zhou B Peter
Department of Molecular & Cellular Biochemistry
University of Kentucky
Zhou B Peter received extensive training in breast cancer research at the Department of Molecular and Cellular Oncology and Breast Cancer Research Program at the MD Anderson Cancer Center prior to the faculty appointment at UTMB and UK Markey.
Department of Pathology
Harbin Medical University
Yu-Fei Jiao received the B.S. degree in clinical medicine from Harbin Medical University, Harbin, China in 1985 and the M.S. degree in pathology from Graduate School of Harbin Medical University, Harbin, China, in 1990. Moreover, he obtained the Ph.D. degree in laboratory medicine and pathology from Graduate School of Kochi Medical School, Kochi, Japan, in 1999.
Department of Experimental Medicine
Lab of Histology and Embryology, Second University of Naples
Vincenzo Desiderio graduated in Pharmaceutical Biotechnology at the University Federico II of Naples with an experimental thesis in onco immunology. He worked as research assistant in both academic and industrial field for few years before joining a PhD program in biotechnology held between the Second University of Naples (SUN) and the University of Michigan (UofM). In 2013 he got the position of Assistant Professor at the SUN lecturing Medical Histology and Embryology in the Medical School program specifically dedicated to international students. His research activity has focused on stem cells biology and cancer stem cells identification and characterization leading to the publication of more then 30 papers in peer review journals. He is member of the Italian Society of Flow Cytometry recognized as expert in the national register of cytometrists.
The lab of Prof. Zena Werb
University of California
San Francisco, United States
Vicki Plaks presently a specialist in The lab of Prof. Zena Werb, University of California, San Francisco and she completed her Ph.D. degree, from The Feinberg Graduate School, Weizmann Institute of Science, Rehovot, Israel and the topic of her Ph. D. thesis is In vivo MRI studies of angiogenesis in reproduction and embryonic development in transgenic mice. She has experience with cases of birth complications and oncology during her internship led her to pursue research at the Weizmann Institute, Israel her M.Sc. studies focused on understanding drug mechanism of action and therapeutic response to a novel anti-cancer vascular photodynamic therapy. Her postdoctoral fellowship at UCSF, California focused on mechanisms governing mammary biology and breast cancer. She is having membership in American Association for Cancer Research (AACR), Member, Society for the Developmental biology (SDB), Member, Society for the Study of Reproduction (SSR), Member and Vicki Plaks is honored with many awards and fellowships.
Vicente Notario graduated with a B.Sc. degree from the University of Salamanca, Spain, in 1974, and received his Ph.D. in Biology from the same institution in 1977. After completing post-doctoral training in the Department of Biochemistry of the University of Cambridge, England, and the U.S. National Cancer Institute, he joined the Department of Biochemistry at the Georgetown University Medical Center (G.U.M.C.) as a Research Assistant Professor, in 1986. Currently, Dr. Notario is Professor in the Departments of Radiation Medicine and of Biochemistry and Molecular & Cellular Biology. He is also Director of the Division of Radiation Research in the Department of Radiation Medicine. Dr. Notario has been Leader of the Radiation Biology & DNA Repair Program and the Molecular Targets & Therapeutic Resistance Program of the Lombardi Comprehensive Cancer Center, at the G.U.M.C. For over twenty years. His laboratory has focused on understanding molecular and cellular mechanisms of cancer initiation and progression as well as those involved in the acquisition of resistance to anti-cancer therapy, with emphasis on pathways that may be exploited to improve the treatment of metastatic cancers and to sensitize human tumors to chemotherapeutic drugs and radiation therapies. Dr. Notario has authored more than 135 publications. The quality and clinical significance of Dr. Notario’s contributions have been recognized and, consequently, continuously funded by the U.S. National Cancer Institute since 1986. Dr. Notario has also received international recognition in the form of numerous invitations to speak at specialized meetings and to become a member of the Editorial Boards of journals such as Cancer Research, The International Journal of Oncology, Current Cancer Therapy Reviews, The Open Cancer Journal, The Journal of Cell Death, The World Journal of Clinical Oncology, and others. Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.
Medical Microbiology, Immunology and Cell Biology
Southern Illinois University
Sophia Ran is an Associate Professor in the Department of Medical Microbiology, Immunology and Cell Biology at SIU School of Medicine and a member of the SIU Simmons Cancer Institute (SCI). Dr. Ran is a member of the American Association of Cancer Research (AACR). She is a coordinator of monthly research seminars in SCI, serves on the organizing committee for the bi-annual SCI Research Symposium as well as on various committees of the School of Medicine.
Siva K Gandhapudi
Department of Physiology
University of Louisville, College of medicine Health Science center
Siva K Gandhapudi completed his Ph.D. in Immunology in University of Kentucky, Lexington, KY and M. S in Soil microbiology University of Kentucky, Lexington, KY. Siva K Gandhapudi is a biomedical Research scientist with more than 9 years’ experience in basic research and 1 plus years’ experience clinical research. He has research expertise in the area of Immunology and research interest in hematopoiesis and Immunotherapy, Vaccine adjuvant development, Inflammation and Immune responses to stress.
Shyamal Dilip Desai
Department of Biochemistry and Molecular Biology
LSU Health Sciences Center
Shyamal Desai is an Assistant Professor in the Department of Biochemistry and Molecular Biology at the Louisiana State University Health Sciences Center-School of Medicine, New Orleans, LA. Dr. Desai obtained her Bachelor of Science and Master of Science in Biochemistry from the University of Bombay, India in 1981 and 1983 respectively. She received her Doctorate in Biochemistry from the University of Bombay, India in 1991. Dr. Desai received New Jersey Cancer Research Award for Scientific Excellence in 1996 and 2003. She also received the American Association for Cancer Research-AFLAC Scholar Award in Cancer Research in 1999. Dr. Desai is serving as an editorial board member of the Journal of Antivirals and Antiretrovirals and the Experimental Cell Biology and Medicine.
Molecular Biology and Immunology
University of North Texas
Sharad Singhal is a recipient of Junior Research Fellowship of council of Scientific and Industrial Research, 1985-1987. Recipient of Senior Research Fellowship of Council of Scientific and Industrial Research, 1987-1989. Postdoctoral Fellow, Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas, 1989-1992. Instructor, Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas, 1992-1997. Assistant Professor, Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas, 1997- Feb 1999. Arlington, Arlington, TX March 1999- October 2004. Arlington, Arlington, TX November 2004-November 2007. Associate Professor, Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Forth Worth, TX December 2007-Present.
Department of Neurosciences
Lerner Research Institute, Cleveland Clinic Foundation Cleveland, OH
Selva Baltan received her MD from Hacettepe University, Turkey, and her PhD in Neurophysiology from McGill University, Canada. She did postdoctoral work at Washington University, MO, USA, and is now assistant professor at the Department of Neurology, University of Washington, WA, USA. Her research focuses on the mechanisms of brain cell damage in white matter after stroke.
Sanjay K Srivastava
Texas Tech University
Sanjay K Srivastava is a Professor of Biomedical Sciences at Texas Tech University Health Sciences Center (TTUHSC), Amarillo, Texas, specializing in cancer biology and nutritional chemoprevention. Prior to his arrival at TTUHSC in 2007, Dr. Srivastava served as an Assistant Professor in the Department of Pharmacology, University of Pittsburgh School of Medicine and was a full member of the University of Pittsburgh Cancer Institute. He also served as Research Scientist at Mercy Cancer Institute, Mercy Hospital of Pittsburgh and did his post-doc from University of Texas Medical Branch at Galveston, Texas. Dr. Srivastava received a B.S. in Physics, Chemistry & Math and a M.S. in Biochemistry from Lucknow University, India. His Ph.D. is in Biochemistry and Toxicology from Industrial Toxicology Research Center, Lucknow and Kanpur University, Kanpur, India. His research interests include cancer biology, chemoprevention of cancers by naturally occurring nutritional agents, chemical carcinogenesis and cell signaling. Dr. Srivastava is currently funded by two R01 grants from the National Cancer Institute, NIH. He has authored more than 100 research papers and book chapters and is a member of the American Association for Cancer Research, Society of Toxicology and AAPS. Dr. Srivastava is in the editorial board of several journals and ad-hoc reviewer of numerous scientific journals including Cancer Research, Carcinogenesis, Neoplasia and Molecular Pharmacology and also member of the study section of the National Institute of Health (NIH), Department of Defense and Susan G. Komen Breast Cancer Foundation. Dr. Srivastava has been recipient of several awards including TTUHSC “President’s Excellence in Research Award”. His research work has been featured by news agencies including BBC, MSNBC, CBS, ABC, Science News etc. and can be obtained from the following: BBC News-Pancreatic Cancer.
Sandip Kumar Mishra
Institute of Life Sciences Nalco Square
Sandip Kumar Mishra is a Scientist-D, Institute of Life Sciences (Govt. of India), Nalco Square, Bhubaneswar-751023, Orissa, India (Since September 2007---continuing) and worked as an Instructor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX-77030, USA, (From 2004-2007). He is an Associate Editor of World Journal of Cancer Research by American Scientific Publishers.
Qingrong Huang, PhD
The State University Princeton Junction New Brunswick, NJ, USA
New Jersey, United States
Qingrong Huang is an Associate Professor, Department of Food Science, Rutgers University at New Brunswick. 9/2008-8/2009 Cluster Coordinator, Nanotechnology Application to Foods Cluster, Center for Advanced Food Technology, Rutgers University 1/2008-present, Full member of Graduate Programs in Molecular Biosciences, UMDNJ/Rutgers University, and Department of Molecular Biology & Biochemistry-Rutgers 1/2003-present, Full member of Graduate Program in Bioresources Engineering-Rutgers University at New Brunswick. 9/2002-6/2008, Assistant Professor, Department of Food Science, Rutgers University at New Brunswick. 1/2000-8/2002, NIST ATP Postdoctoral Research Associate, Department of Chemical Engineering, Stanford University/IBM Almaden Research Center Advisors: Drs. Curtis Frank and Robert Miller 2/1999-3/1999 Visiting Scientist, Intense Pulsed Neutron Source Division, Argonne National Laboratory. 6/1998-1/2000, Postdoctoral Research Associate, Department of Chemistry, Indiana-Purdue University, Advisor: Dr. Paul Dubin2 8/1993-5/1998, Research/Teaching Assistant, Department of Chemistry, University of Nebraska-Lincoln. 9/1989-7/1993, Research Assistant, Laboratory of Polymer Physics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences. 2010 American Chemical Society Young Scientist Award finalist. Distinguished Speaker, College of Agricultural, Consumer & Environmental Sciences, University of Illinois, November 19, 2009. Received 2007-2008. The Professor Endel Karmas Award for Excellence in Teaching Food Science, Department of Food Science, Rutgers University. Honorable Speaker for the Polymer Science Lecture Series, State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, May 2007. Honorable Speaker for the Polymer Science Lecture Series, State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, May 2006.
Professor of Medicine
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
Professor Barbara Jarzab M.D., Ph.D., endocrinologist and nuclear medicine specialist, head of Department of Nuclear Medicine and Endocrine Oncology at Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, a comprehensive cancer center and research institute that takes care of Silesian patients, an industrial part of Poland with 4,6 million population. Areas of research involvement: functional genomics of endocrine tumors with focus on gene expression profiling of thyroid cancer and genetic predisposition to endocrine disease (thyroid cancer, pheochromocytomas, Graves disease). Clinical activity: radioiodine therapy of differentiated thyroid cancer and benign thyroid disease, radiopeptide imaging and therapy of neuroendocrine tumors, new methods of diagnosis and therapy of progressive endocrine gland cancer, including multikinase inhibitors clinical trials in thyroid cancer. Coordinator of multidisciplinary consortium which introduced first in Poland DNA microarray technologies implemented in analysis of cancer transcriptome. Correspondent Member of Polish Academy of Arts and Sciences and correspondent Member of Polish Academy of Sciences, member of the Committee for Human Genetics and Molecular Pathology of the Polish Academy of Sciences, President of Polish Group of Endocrine Tumors of Polish Society of Endocrinology, Acting Representative of European Task Group for Endocrine Cancer. Previous positions: Secretary of European Society of Endocrinology, Secretary of European Thyroid Association – Cancer Research Network, member of European Thyroid Association Executive Committee.
Mazin Al Salihi
Division of Cardiothoracic Surgery
Emory University School of Medicine
Prior to coming to the United States, Dr. Al Salihi was an attending cardiac surgeon at Ibn Al Bittar Cardiac Surgery in Baghdad; held several positions at the Iraqi Center for Heart Diseases, including general director; and worked as a cardiac surgeon at Al-Issra General Hospital in Amman, Jordan. Upon arriving in the states in 2008, he studied for the three steps of the United States Medical Licensing Examination (USMLE) and recertified his credentials at Kaplan Institute, Akron, Ohio. He then joined the Cleveland Clinic as a clinical associate staff surgeon while completing fellowships in cardiac surgery and heart and lung transplantation. He joins Emory as its first surgeon dedicated primarily to heart and lung procurement for transplantation. His clinical interests also include minimally invasive valve surgery and VATS thoracic surgery, and his research focus is ex vivo lung perfusion.
Porunelloor A Mathew
Molecular Biology and Immunology
University of North Texas
Porunelloor A Mathew is an Associate Professor of Molecular Biology and Immunology, University of North Texas Health Science Center at Fort Worth, and Associate Director for basic research, Institute for Cancer Research, UNTHSC, Fort Worth, Texas. Dr. Mathew received his PhD in Biochemistry in 1987 from University of Pune, India. He did postdoctoral fellowships at University of Medicine and Dentistry of New Jersey and UT Southwestern Medical Center. He is a reviewer for several journals. Dr. Mathew was awarded a US patent for “Immuno activation of CS1 receptor in Natural Killer cells to inhibit tumor cell growth”. Dr. Mathew’s research has opened new NK cell based targeted immunotherapy for cancer.
Professor & Director
NIH RCMI Center for Environmental Health
Jackson State University
Paul Tchounwou is an Associate Dean of the College of Science, Engineering and Technology, Presidential Distinguished Professor & Director of the NIH RCMI-Center for Environmental Health and at Jackson State University, Jackson, Mississippi, USA. He earned his Sc.D. at Tulane University Medical Center (TUMC), New Orleans, Louisiana, USA. Currently, he is also Adjunct Professor at TUMC. He has published 134 peer-reviewed papers and book chapters, and made over 300 presentations at national and international conferences. He is currently Editor-In-Chief of International Journal of Environmental Research and Public Health (MDPI, Basel, Switzerland), and of Environmental Toxicology (John Wiley & Sons, New York, USA). He has taught toxicology, epidemiology, risk assessment and public health-related courses for more about 20 years. He is member of Delta Omega Honorary Public Health Society, American Association for the Advancement of Science, American Association for Cancer Research, American Public Health Association, National Environmental Health Association, Society of Toxicology, and New York Academy of Science. He is a reviewer of journals in the area of toxicology and health risk assessment. He has received several awards including the Millennium Award for Excellence in Research; National Role Model Award; AACR Faculty Scholar Award for Cancer Research and International Order of Merit.
Noula D Shembade
Microbiology and Immunology
University of Miami
Noula D Shembade is an Assistant Professor of the Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami FL June 2008- June2009 Associate Scientist, Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami FL May, 2005- June 2008 Post-Doctoral Associate, Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL , USA.
School of Medicine, University of Pennsylvania
My interest in cancer research started when I undertook a dissertation project during my undergraduate studies at the Division of Molecular Oncology, Institute of Cytology and Preventive Oncology (ICPO), under the guidance of Dr. B.C. Das (Founder Director of ICPO, India). This research was focused on dissecting the relationship between human papilloma virus and AP-1 transcription factor in the development of oral cancer. I had the opportunity to work with biopsy tissue specimens from patients with oral premalignant lesions. During this project, I learned numerous molecular biology techniques and inherently developed a strong penchant to pursue a research career in the oral cancer field. After qualifying through a competitive nationwide exam, I was awarded a prestigious five-year predoctoral fellowship from the CSIR foundation, India. As a CSIR research fellow, I joined ACTREC, a pioneering institute dedicated to cancer research in India. My Ph.D. research in Dr. Maru’s laboratory involved studying the chemopreventive role of dietary curcumin in regulating phase I/II enzymes in vivo via AhR and Nrf2 transcription factors. Moreover, I demonstrated that curcumin regulates phorbol ester-induced biochemical and molecular alterations in murine skin via protein kinase C. With the notion of identifying potential clinical biomarkers and to continue my research interest, I studied the effect of dietary turmeric at different stages of oral carcinogenesis in an experimental animal model. I observed that dietary turmeric modulates DMBAinduced p21, MAPKinases and transcription factors (AP-1 and NF-kB) to alter cellular responses related to inflammation, proliferation and apoptosis. In Dr. Maru’s lab, I acquired significant expertise in molecular carcinogenesis and chemoprevention and became highly proficient in the use of in vivo models, including DMBA-induced hamster buccal pouch model of oral cancer. My time in his lab was very productive, with my thesis work culminating with six publications, (four as first author: Garg et al. Carcinogenesis 2008; Garg et al. Carcinogenesis 2008b; Garg et al. Toxicol Appl Pharmacol 2008 and Garg et al. JEPTO 2009), a book chapter, and a review article. I am proud that my work led to several prizes and awards at national/international conferences. I then intended to extend my research to a challenging area: to explore the signaling networks underlying carcinogenesis with the purpose of providing a molecular basis for drug design. Therefore, I moved to the US to join Dr. Marcelo Kazanietz’s Laboratory at the University of Pennsylvania, as a postdoctoral fellow. Dr. Kazanietz is one of the prominent researchers in the field of PKC signaling and cancer. Initially, I started with an ongoing project in the laboratory wherein we observed that transgenic overexpression of PKCe in the mouse prostate induces preneoplastic lesions, and I was the co-author of a 2011 Cell Cycle paper reporting the results of the work. Our study was highlighted in the News and Views Section of Cell Cycle. Dr. Kazanietz then allowed me to design my own project in which I combined my doctoral expertise with the knowledge of PKC biology acquired in his laboratory and successfully demonstrated, through a mechanistic study, that PKCe facilitates the assembly of TNFR-I complex to regulate the NF-kB pathway in prostate cancer (Garg et al., JBC 2012). My thorough bioinformatics analysis to dissect the transcriptional networks controlled by PKC isozymes recently resulted in another first-authored publication (Garg et al, PLoS One 2013). Besides, I encapsulated our current understanding of PKCs in a recently published review article (Garg et al, Oncogene, 2013). I am currently working on two projects that are close to submission to major journals. In the first, by means of cellular and transgenic mice models, I demonstrated that COX-2, a well-known NF-kB regulated gene, acts as a potential mediator of PKCe oncogenesis in prostate cancer, a study that has been supported by a postdoctoral fellowship from the United States Department of Defense. As the PI of this DOD-sponsored grant, I gained experience in cellular, genetic, pharmacological and bioinformatics approaches to delineate signaling pathways that contribute to malignant transformation and developed skills working with xenograft and transgenic mice models. In the second, I identified cooperativity between PKCe and Pten loss for prostate cancer progression.
Division of Cancer Control and Population Sciences
Epidemiology and Genomics Research Program , National Cancer Institute
Mukesh Verma is Chief of the Epidemiology and Genomics Research Program′s (EGRP). Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP′s former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI′s Division of Cancer Prevention (DCP). He also was Coordinator of DCP′s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.
Department of Molecular and Cellular Oncology
University of Texas
Mong-Hong Lee is currently Professor in the Department of Molecular and Cellular Oncology of University of Texas MD Anderson Cancer Center and a faculty member at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS). In 1993, Dr. Lee received his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh, where he received the Stanton C. Crawford Award for teaching excellence. He then went on to complete a postdoctoral fellowship while serving as a research associate at Howard Hughes Medical Institute and Memorial Sloan-Kettering Cancer Center (1993-1997). After completing his fellowship, Dr. Lee came to M. D. Anderson in 1997 as an Assistant Professor (tenure track). He was promoted to his current position of Professor (tenured) in 2010. During his time at M. D. Anderson, Dr. Lee has been the principal investigator or a co-principal investigator for nine funded research projects. He also has been a grant reviewer for several funding agencies. Dr. Lee has been honored for his research activities, led by the Susan G. Komen Breast Cancer Foundation Research Award (2001), Fleming and Davenport Research Award (2001), and William G. McGowan Foundation Research Award (1998). In addition to research, for more than a decade, Dr. Lee has been a key contributor to the education of trainees at M. D. Anderson and the GSBS in a variety of ways. For example, at the GSBS, he has been the course coordinator for the Molecular Genetics of Human Cancer seminar since 2006 and an instructor for the Cancer Cell Signaling course since 2000. Dr. Lee has had a wealth of direct interaction with trainees throughout his career. Specifically, he has directly supervised 40 graduate students, 12 clinical residents and fellows, 12 undergraduate and Allied Health students, 9 postdoctoral research fellows, and 1 medical student. Furthermore, he has chaired or served on 71 examining committees, 67 advisory committees, and 39 supervisory committees. UT M. D. Anderson Cancer Center and the UT GSBS at Houston have well recognized Dr. Lee’s educational efforts. In 2009, he received the John P. McGovern Outstanding Teaching Award, which is given annually to a faculty member at M. D. Anderson and/or the GSBS. Most recently, he has recently been named the February 2010 Faculty Educator of the Month at MD Anderson Cancer Center. Also, he received the M. D. Anderson Outstanding Educator Award in 2003. Currently, Dr. Lee is an ad hoc reviewer for 25 journals. He also has been a guest editor for the journal Breast Diseases. Over the course of his career, Dr. Lee has authored more than 50 articles published in peer-reviewed journals, 4 book chapters, and 3 invited articles.
National Institute of Health & Family Welfare
MM Misro is Professor in Reproductive Biomedicine in the National Institute of Health and Family Welfare, New Delhi, India. He is a postgraduate in Zoology with specialization in Physiology and Biochemistry and completed his PhD in Male reproductive Physiology with special emphasis in Contraceptive Technology Development. He was Fellow of Rockefeller Foundation and did his post-doctoral training in the Department of Pharmacology in the University of Iowa during 1984-1986. He is currently a member of the Editorial Board in the International Journal “Current Women’s Health Reviews and peer reviewer for many International Journals.
Director of the Unit of Cancer
Hospital General Virgen de la Luz in Cuenca
MJ Molina-Garrido is presently Director of the Unit of Cancer in the Elderly Hospital Virgen de la Luz de Cuenca. She is having a Master degree in Geriatrics and Gerontology at the Autonoma University of Barcelona. She has received a Doctor of Medicine from the Universidad Miguel Hernández de Elche.
Mfon Samuel Cyrus-David
The University of Texas Health Science Center
Mfon Samuel Cyrus-David is a Principal Investigator, the University of Texas Medical School at Houston Cancer Bioinformatics Program (UTHealth-HMS CaBIP). The faculties of this program meet on a monthly basis to evaluate its progress, and plan for the future. The objectives of the UT Health-HMS CaBIP are to design, integrate, implement, operate and maintain cancer site-specific databases on all the types of cancers that are managed at the UT - Memorial Hermann Cancer Center, and the affiliated health establishments of the UT Medical School Houston, TX, such as the Memorial Hermann Hospital (MHH) at the TMC, and the Harris County Hospital District’s (HCHD) Lyndon B. Johnson General Hospital, Houston Texas, and its satellite health centers.
Marighoula Varla Leftherioti
Head of the Immunobiology Department and the Recurrent Abortion Outpatient Clinic
General District-Maternity Hospital “Helena Venizelou”, Athens
Medical Doctor specialized in Medical Biopathology – Immunology, possessing a Doctorate from the Medical School of the “National and Kapodistrian” University of Athens, Greece. She is involved in Immunology since 1979 and is familiar with all lines of Laboratory Immunology with professional experience in the Immunology Departments of big hospitals in Athens area and training in European Immunology Departments. She has worked on the pre- and post-transplant immunological monitoring of kidney recipients, on HLA-typing for disease associations. She worked as Director to the Hellenic Transplant Service and established the first Bone Marrow Donor Registry in Greece. Her current interest is Reproductive Immunology and the investigation of couples with immune-mediated fertility problems. Her research interest focuses on the study of NK cells in pregnancy failure and on the effect of intravenous immunoglobulin G infusions (IVIG) on the immune response of aborting women (Th2 shift). With her team, she was the first to investigate the role of the NK cell receptors’ repertoire in couples with RSA, to present the role of a KIR/HLA-C allorecognition system in pregnancy, and to suggest that specific combinations of maternal inhibitory KIRs and fetal HLA-C molecules may provide reduced NK cell inhibition at the feto-maternal interface and predisposition to implantation failure and/or fetal loss. During the last years she has started studies on Pre-Implantation Factor – PIF. Apart from her scientific work, she is an active member of Scientific Societies (three times President of the Hellenic Society of Immunology), and current President of the European Society for Reproductive Immunology (ESRI).
Matthew E Witek
Assistant Clinical Professor
University of Wisconsin-Madison
Matthew Witek received his Master’s in Clinical Pharmacology from Thomas Jefferson University in Philadelphia, Pennsylvania in 2003. He worked in Dr. Scott Waldman’s laboratory evaluating the role of enterocyte-specific proteins in the development and management of gastrointestinal malignancies. Matthew then studied medicine at Jefferson Medical College and pursued a Radiation Oncology Residency from 2010-2014 at Thomas Jefferson University Hospital. During this time, he evaluated the temporal relationship between combined radio- and immunotherapy in the laboratory of Dr. Adam Snook. Matthew currently is Associate Professor of Radiation Oncology at the University of Wisconsin in Madison, Wisconsin where his clinical practice focuses on skin cancers and malignancies arising in the head and neck region.
Matteo A Russo
Department of Experimental Medicine
University of Rome Sapienza
Matteo A Russo graduated in Medicine and Surgery (1969), Catholic University of Rome. Italy. He is Assistant Professor of General Pathology (1970), University of Rome, Sapienza, Italy. Associate Professor of Experimental Oncology (1980), University of Rome, Sapienza. Full Professor of General Physiopathology (1986), University of Rome, Sapienza, Italy. Fulbright Scholar 1974-1976, University of Pennsylvania and Temple Univ, Phila., Pa., USA. Visiting Professor of Pathology, Thrombosis Center, Temple University, Phila (1977-1979). Adjunct Professor of Pathology and Pharmacology, (1980-1990). Temple University, Phila, Pa.USA. He has obtained many research grants, both in USA (US-Environmental Protection Agency#CR-808949 and WW Smith Charitable Trust) and Italy (MURST, CNR, AIRC, etc). Award for Experimental Oncology, Fondazione Assicurazioni Generali di Trieste (1982). Member of many scientific Societies (SIP, SIC, etc.) Member of the Superior Committee of Public Health (2003-2005). Director of the Research Doctorate in Human Pathology of Univ of Rome, Sapienza. Malpighi award from the Malpighi and Holding International Altay Foundation (2005) Member of the National Committee for the Research of the Ministry of Health (2000-2009). Member of the Scientific Committee for the Excellence Centre of “Regione Lazio” (2006-). President of Biomedical Laboratory Technician School at Sapienza University of Rome. President of Ethical Committee of ASL of Frosinone, Italy (2004-2010) Member of Scientific Committee of IRCCS San Raffaele Pisana, Rome.
Department of Hematology and Biomedical Oncology
School of Medicine, Emory University
Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-); Visiting Professor in Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA (2012–2013); Visiting Professor in Department of Pathobiology, College of Veterinary Medicine, The University of Missouri-Columbia, MO, USA (2012); Visiting Professor in Department of Foods and Nutrition, The University of Georgia, GA, USA (2011 – 2012); Visiting Professor in Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, GA, USA (2007 – 2011); Professor in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1993 ~ August 2007); Associate Professor in Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1991~1993); Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka, Japan (1987~1991); Visiting Assistant Professor in The University of Texas Medical School at Huston, USA (1988); Assistant Professor in Shizuoka College of Pharmacy, Japan (1986~1987); Visiting Assistant Professor in Texas Tech University School of Medicine, USA (1985); Visiting Lecturer in The University of Pennsylvania School of Medicine, USA (1981); Research Associate in Shizuoka College of Pharmacy, Japan (1973 ~ 1986). He received a Ph.D. in Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has completed his B.S. in Pharmaceutical Sciences, Shizuoka, Japan (1971). Dr. Yamaguchi is engaged in the fields of bone and calcium endocrinology and cell calcium signaling since 1971, and these researches are developed in the aspect of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology, and toxicology. Dr. Yamaguchi has an interesting for cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetic osteoporosis, and cancer bone metastasis and osteolysis. Moreover, Dr. Yamaguchi discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978) and transcriptional factor RGPR-p117 (regucalcin gene promoter region-related protein; 2001) in mammalian cells. Dr. Yamaguchi generated regucalcin transgenic rats, which were registered as international patents (USA, EU, Japan, and Korea), and this animal is found to induce osteoporosis and hyperlipidemia. Recently, Dr. Yamaguchi proposes that regucalcin is a target molecule in carcinogenesis of various cancer cell types. Currently, the research of regucalcin is focused as a scientific topic. Dr. Yamaguchi published over 500 English articles to professional journals with peer-review. In addition, Dr. Yamaguchi registered over 20 national and international patents in the fields of his research interesting. Dr. Yamaguchi is serving as editors and editorial board members of reputed 40 international Journals. He received many honor and awards; Prize for Sato Memorial Fundation (1992, Japan/USA), Senji Miyata Foundation Award 2005 (Japan), Japan Society for Biomedical Research on Trace Elements Award 2007, The Lifetime Achievement Award from International Biographical Centre (IBC) (2004, England), The World Lifetime Achievement Award from American Biographical Institute (2004, USA), The Distinguished Service to Science Award from IBC (2007, England), and many others. Dr. Yamaguchi is listed in various biographies; Who’s Who in the World (2005-, Marquis Who’s Who, USA), Who’s Who in Sciences and Engineering (2004-, Marquis Who’s Who, USA), International Biographical Dictionary (2006-, IBC, England), and others.
Research Assistant Professor
Department of Pathology and Laboratory Medicine
University of Pennsylvania
Philadelphia, United States
Kar Muthumani is Research Assistant Professor at the Department of Pathology and Laboratory Medicine, University of Pennsylvania. He received his BS, MS with honors and his PhD from the Madurai Kamaraj University, India. He completed his postdoctoral training at the University of Pennsylvania School of Medicine, PA, USA.
Kailash C Chadha, PhD
Molecular and Cellular Biology
Roswell Park Cancer Institute
Kailash C Chadha is an Associate Member, Department of Molecular and Cellular Biology Roswell Park Cancer Institute Buffalo NY 14263 Associate Research Professor, Department of Cellular and Molecular Biology University of New York at Buffalo Roswell Park, Associate Professor of Oncology, Roswell Park Cancer Institute Buffalo, Research Professor Niagara University, New York 14109 and Research Assistant Professor of Medicine, Department of Medicine School of Medicine State University of New York at Buffalo NY 14214, USA.
Department of Cancer Biology
The Scripps Research Institute
Junpeng Qi received his Ph.D. degree from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences in 2012. He then joined Eli Lilly China Research and Development Center as a Research Scientist developing new drugs for Type II Diabetes. And now, he is a research associate focusing on antibody engineering for cancer therapy at The Scripps Research Institute, Florida.
Jon S. Cardinal
Department of Surgery
West Virginia University
Jon Cardinal, MD FACS is an Assistant Professor and Surgery Program Director at the West Virginia University School of Medicine. He completed his undergraduate degree at Duquesne University after which he matriculated at Georgetown University Medical School, graduating AOA. His general surgery internship and residency were completed at the University of Pittsburgh Medical Center (UPMC) followed by a one-year fellowship in hepato-pancreatico-biliary (HPB) surgery, also at UPMC. During his surgical training, Dr Cardinal actively participated in basic science research in which he investigated the molecular mechanisms responsible for sterile inflammation. Dr Cardinal joined the department of surgery at WVU in 2012 and has been the program director for the general surgery residency since 2014.
Jing Gung Chung, PhD
Biological Science and Technology
China Medical University
Jing-Gung Chung is a Professor, Chairman, Department of Biological Science and Technology, China Medical University, Taichung, Taiwan (2002-2005) and Associate Professor, Department of Microbiology, School of Medicine, China Medical University, Taichung, Taiwan (1993-2002).
Department of Surgery
West Virginia University School of Medicine
Jessica Partin, MD is an assistant professor in the Department of Surgery in the West Virginia University School of Medicine and Chief of Breast Surgery at West Virginia. She earned her medical degree at Eastern Virginia Medical School in Norfolk, Virginia amd completed a residency in general surgery at WVU in Morgantown, WV. She also completed a Society of Surgical Oncology Breast Oncology Fellowship at Akron General Medical Center, in Akron, Ohio. She stayed on as staff at Akron General Medical Center and served as the Medical Co-Director of the Reflections Breast Health Center and as assistant program director for the Breast Oncology Fellowship and also served as a clinical associate professor at Northeast Ohio Medical University. In addition, she worked as a clinical consultant of the Breast Care Center for the Aultman Hospital Foundation in Canton, Ohio. Since coming to West Virginia University, Dr. Partin serves as the Chair of the Breast Program Leadership and as the CoC Cancer Liaison Physician.
Institute of Biophysics, Federal University of Rio de Janeiro
Janaina Fernandes is an Adjunct Professor of the Institute of Biophysics at Federal University of Rio de Janeiro. She has received a PhD in Biophysics from the Institute Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro. 2001-2005. Received the Carlos Chagas Filho Awards (2008). She is serving as reviewer for the Lung Journal (New York) and as reviewer for research grant application for the Brazilian Health System, Brazilian Health Ministery, and as Editorial board Member for the Journal of Bioequivalence & Bioavailability and Journal of Bioanalysis & Biomedicine. She is author and co-author of international patents and articles on medicinal chemistry, mostly in natural products research.
Jagat R Kanwar
Immunology and Molecular Biomedical Research Institute for Technology Research & Innovation, Deakin University
Jagat R Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer. Dr. Kanwar has published 55 research articles, 12 invited reviews and 5 book chapters, in highly ranked, international, peer-reviewed journals. These publications have added to the body of knowledge in the fields of immunology, cancer gene therapy, nanomedicine, cell biology and biotechnology, and have extended these disciplines. He is a key inventor on 9 international patents and has provided consultancy to 5 Biotechnology based companies. He is a member of editorial board for 7 international journals and a nominated member of more than 12 national and international societies including American Society of Nanomedicine. He has extensive and close collaborations with colleagues from New Zealand, Australia, Singapore, India, China and USA.
Gloria I Sanchez
Group Infection and Cancer Lab
University of Antioquia
Gloria I. Sanchez is an Associate professor in the School of Medicine at the University of Antioquia in Medellin, Colombia and leader of the research group Infection and Cancer. She earned her Ph.D. in Molecular Microbiology and Immunology from the Johns Hopkins Bloomberg School of Public Health in 2000 at which time she joined the University of Antioquia where she started a research program focusing on the area of Human Papillomavirus (HPV) and Cancer. From 2004-2006, she completed Postdoctoral Fellowships at the Catalan Institute of Oncology in Barcelona, Spain, at the Department of Internal Medicine and Human Genetics at University of Michigan, Ann Arbor Michigan. During postdoctoral training, she participated in a multicenter worldwide study defining the time trends of HPV infection in cervical cancer and defining the role of HPV on Head and Neck and other human cancers.
Gary Guishan Xiao
Genomics and Functional Proteomics Laboratories, Creighton University
Gary Guishan Xiao is a Director of the Functional Genomics and Proteomics laboratories at the Creighton University. Osteoporosis Research Center is an internationally recognized expert in the field of proteomics and metabolomics of cancers and bone disease. Dr. Xiao earns his Ph.D. in molecular computational biology about a dozen years ago, focusing on structural modeling of ligand-enzyme interaction and prediction of protein refolding pathways during protein translational process. Dr. Xiao had his postdoctoral research trained in Baylor College of Medicine and UCLA, focusing on pharmacokinetics and biochemistry of non-steroid inflammatory drugs such as aspirin-derivatives and their target, human prostaglandin H synthases H1 and H2, and cell cycle regulation, especially, the role of c-Myc in cardiac termination differentiation. Dr. Xiao’s research at harbor UCLA medical Center and City of Hope National Cancer Center were highly focused on genomic and proteomic interpretations of diet-induced obesity/diabetes and its complications such cancers and osteoporosis. Dr. Xiao joined Osteoporosis Research Center at the Creighton University Medical Center since 2007. Dr. Xiao has been regular reviewer or ad hoc reviewer for several medical journals, different funding agency such as NIH and several journal Editorial Board members.
Maria Angelica Cortez
The University of Texas MD Anderson Cancer Center Houston, Texas
Texas, United States
From an early age, I have had both a curious nature and a passion to reduce human affliction, and these traits led me to a career in oncology research. Since 2004, I have been focusing on the identification of novel drug targets for cancer. During my Master’s and Ph.D program at University of Sao Paulo, one of the most prestigious academic centers in Brazil, I focused on mechanisms of resistance to standard chemotherapy in acute Leukemias and the molecular pathways underlying Glioblastoma tumorigenesis. Upon completing my Ph.D. program, I was recruited to MD Anderson to pursue analogous translational research projects. As a postdoctoral fellow at MD Anderson Cancer Center, I was afforded the opportunity to explore cutting-edge science in exciting and novel areas of microRNA and long noncoding RNAs with potential roles in cancer at Dr. George Calin’s lab. Since 2011, I joined Dr. James Welsh’s laboratory to explore new mechanisms of tumor immune evasion and identification of new potential therapeutic targets to overcome resistance to immunotherapies in combination with standard therapies such as radiation.
Division of Radiological Sciences
Washington University School of Medicine, Mallinckrodt Institute of Radiology
FEI Han is currently working as Visiting scholar, Department of Radiology, Washington University School of Medicine in Saint Louis (2006-present) Attending Doctor & Instructor, Department of Pathology, Tongji Hospital, Tongji University School of Medicine (2013-2015). Resident Doctor, Department of Pathology, Shanghai Chest Hospital Affiliated Shanghai Jiaotong University (2010-2013) Research Assistant, Department of Nephrology, Shanghai Sixth People’s Hospital Affiliated Shanghai Jiaotong University (2009-2010).
Division of Inflammation Biology
La Jolla Institute for Allergy & Immunology
Fan got his Ph.D. from Fudan University, China, and he worked in Xunbin Wei’s lab to study cancer and immunology using biomedical optical imaging. Fan has participated in developing the home-made optical instrument – in vivo flow cytometer (IVFC), which enable non-invasive and real-time monitoring of circulating cells in vivo, and made it work in dual colors. He established high-metastatic orthotopic hepatocellular carcinoma (HCC) mouse model and monitored the dynamics of circulating tumor cells (CTCs) using our IVFC.
Nicholas van Panhuys
Department of Translational Medicine
Asthma and Allergy Group, Sidra Medical and Research Center
Dr. van Panhuys received his Ph.D. in Immunology from the University of Otago, Dunedin, New Zealand in 2007, for work conducted at the Malaghan Institute of Medical Research and his BSc(Hons) in Molecular Biology and Biochemistry from Victoria University, Wellington, New Zealand in 2002. Following his Ph.D. Nicholas was awarded the NZ Foundation for Research Science and Technology Post-Doctoral Fellowship Award to travel to the US National Institutes of Health (NIH) in Bethesda, Maryland and was subsequently appointed as a Research Fellow in the National Institute of Allergy and Infectious Diseases in 2012. Dr. van Panhuys subsequently joined Sidra in 2015 as a principle investigator to establish a group specializing in asthma and allergy research.
Thomas G Bird
Senior Clinical Research Fellow
Honorary Consultant in Hepatology
Dr. Thomas G Bird qualified in Medicine from Oxford in 2002. He is now an Honorary Consultant Hepatologist in the Scottish Liver Transplant Unit in Edinburgh. He gained a PhD (2011) studying liver regeneration with Professors Forbes and Iredale investigating stem cell mediated liver regeneration and has published high impact papers on the role of liver progenitor cells in regeneration. He is currently a Wellcome Trust Clinical Intermediate Fellow based at the Beatson Institute for Cancer Research. In addition to his research in liver regeneration he leads research to optimize the use of serum biomarkers in hepatocellular carcinoma surveillance.
Smita S. Chandran
National Cancer Institute, National Institutes of Health
Dr. Smita Chandran received her Ph.D. in Immunology from the University of Maryland at Baltimore in 2009. She then trained as a postdoctoral fellow at the Vaccine Research Center, NIAID, NIH from 2009-2011. She is currently a Research Fellow at the Surgery Branch, national Cancer Institute, National institute of Health in Bethesda.
Ingram Professor and Vice Chair Associate, Director of Education
Department of Cancer Biology
Vanderbilt Ingram Cancer Center
Dr. Richmond received her PhD from Emory University in 1979. She joined Vanderbilt University Dept. of Cell Biology 1989. Currently, she serves as the Ingram Professor of Cancer Biology and Vice Chair of that department. A major question we are trying to answer in my laboratory is "What is the role of the inflammatory response in tumor progression". We are studying the role of proteins that promote the migration of inflammatory cells into tissues. These "chemotactic" proteins can educate leukocytes to either stimulate or inhibit tumor progression. These factors can also stimulate the growth of the tumor and recruit blood vessels into the tumor to provide a continuous supply of nutrients to feed tumor growth. We have tested with a variety of pharmaceutical drugs that shut down the inflammatory process and alter the expression of genes that recruit inflammatory cells into the tumor microenvironment. We are also evaluating how to deliver therapies that teach the patient's leukocytes to fight the growth of the tumor and switch from a pro-tumorigenic to an anti-tumorigenic state. We have also learned that this inflammatory process, combined with other genetic and environmental factors, contributes to mutations in genes that regulate the growth of cells. Some of these mutations make the cells capable of continuous growth and enable the cancer cells to spread throughout the body and grow in distant organs. By determining what genes become mutated or amplified in each patient's tumor and then providing therapies that specifically inhibit the activity of that mutated or amplified gene, we can deliver "personalized cancer treatment" that addresses the problem in that person’s specific cancer. This works so much better than the "one size fits all" approach often used previously in chemotherapy. Recently we have determined that inhibition of aurora kinases induce tumor cells to undergo senescence and when we inhibit aurora kinases while at the same time activate the tumor suppressor p53 or the death receptor DR5, melanoma cells die and tumors regress. We are also interested in evaluating how therapeutic agents that target driver mutations such as PI3K, RAS or BRAF affect the tumor microenvironment and the immune response to the tumor. We postulate that in some instances drug resistance comes in part due to deleterious effects of the therapy on the tumor microenvironment. We collaborate with medical oncologists, surgical oncologists, bioengineers, cellular and molecular biologists, and scientists in pharmaceutical companies to address the scientific questions we are asking. This TEAM interaction enables us to optimize our studies to make important breakthroughs in tumor biology and tumor therapy. Our research is funded by the TVHS Department of Veterans Affairs, the National Cancer Institute, and the Department of Defense. I work with a wonderful group of postdoctoral fellows, students, and laboratory scientists who dedicate their lives to providing better treatments for cancer patients.
Postdoctoral Research Associate
St. Jude Children's Research Hospital
Dr. Rajendra Karki is elucidating the roles and regulation of NLRs in inflammasome-dependent and -independent functions in inflammatory and infectious disease models. During this time, he identified novel functions for several members of the NLR family in infection, inflammation and cancer. He has contributed to a total of 23 peer-reviewed research publications and reviews (eg. Cell, Cell Host Microbe, Nature Immunology, Journal of Experimental Medicine, Journal of Clinical Investigation).
Department of Anatomy and Neurobiology
University of Tennessee
Dr. Qiang Nai received his medical degree from the Shandong Medical University, China, and Master of Public Health from Beijing Medical University, China. He obtained PhD degree in Neuroscience from the Medical College of Ohio in 2002. Dr. Nai did the post-doctoral training in neuroscience at the University of California, San Diego, and the Centre for Addiction and Mental Health, Toronto, Canada. He joined the faculty at the Department of Anatomy and Neurobiology, University of Tennessee, Health Science Center in 2007. His academic activities resulted in a number of articles published in high profile journals. Dr. Nai has interest in becoming a physician-scientist, and he joined the residency program in internal medicine at the Raritan Bay Medical Center in 2013. He developed intense interest in Hematology and Oncology and has been actively involved in multiple projects in the clinical research and cancer patient management.
Associate Professor of Cancer Biology
University of Hawaii Cancer Center, University of Hawaii
Dr. Peiwen Fei has been independently leading research programs for nearly ten years by the end of academic year 2014-15. During this period, she and her team have worked very diligently and obtained sustained-NCI funding since early 2009 (up to 2019 at the moment). Peers have recognized her work as a leading field in the utilization of the Fanconi Anemia-BRCA tumor-suppressor pathway to provide novel insights into our understanding of human tumorigenesis and cancer treatment, and our publications were highlighted in four different scientific news media). Dr. Fei has also established both domestic and international collaborations to help others and improve ours. In addition, Dr. Fei have actively served University of Hawaii as well as scientific communities (journal board member, Journal editor, Journal reviewer, and Grant reviewer for both Federal and non-federal grant applications).
Mukesh K. Pandey
Department of Radiology
Dr. Mukesh K Pandey has received his PhD in Synthetic Organic and Natural Product Chemistry from the University of Delhi, during the period of 2000-2005. Currently, he is working as an Assistant Professor of Radiology at Mayo Clinic Rochester MN USA. He is serving as an editorial member of reputed journals like American Journal of Nuclear Medicine and Molecular imaging and the Journal of Cancer Science and Therapy. He has authored twenty-nine research articles/book chapters. He is a member of the Royal Society of Chemistry London and the American Chemical Society. He holds a designatory title of MRSC honored by the Royal Society of Chemistry London. He is one of the recipients of the Radiology advanced award from the Mayo Clinic Rochester MN in the year 2012.
Department of Pathology
University of Arkansas for Medical Sciences
Dr. Monzavi-Karbassi is an Assistant Professor in the Department of Pathology at University of Arkansas for Medical Sciences, Little Rock, AR, USA. Dr. Karbassi received his Ph.D. in Molecular Biology from Institute of Molecular genetics, Russian Academy of Sciences, Moscow, Russia in 1997. He then did a postdoctoral training in Immunology and tumor biology at the University of Pennsylvania, Philadelphia, PA, USA from 1998 to 2002. He has published more than 40 research articles and earneda broad national and international recognition in his field. He has been serving as a reviewer for several cancer-related journals and on multiple grant review panels.
Department of Microbial Science and Host Defense
Meiji Pharmaceutical University
Dr. Matsui received his Ph.D. in Microbiology from Meiji Pharmaceutical University, Tokyo, Japan. He has been studying the role of colonization by Staphylococcus aureus in patients with atopic dermatitis from 1999. His previous studies demonstrated that cell wall components of S. aureus contributed to an increase in mast cells, Th2 cells and eosinophil numbers in the dermis of skin lesions of atopic dermatitis patients, and also, they induced up-regulation of allergen specific IgE production and Th2 cells development. His current research interest focuses on regulation of Th1/Th2 cells development through Langerhans cells in order to cure allergic disease.
Carlos E Marroquin
Immunology and Hepatobiliary Surgery
University of Vermont
Dr. Marroquin has a background in transplant, general and surgical oncology and leads the transplant team at The University of Vermont Medical Center. He is committed to delivering comprehensive and quality care in the clinical setting to provide patients with the most current and appropriate treatment. Dr. Marroquin works with patients through evaluations, operations and post-surgical follow-ups. He has won numerous teaching awards and was a Delford Stickel Memorial Transplant Surgery Fellow at Duke University Medical Center. His research interests include multiple aspects of transplant surgery, particularly the improvement of quality measures related to transplant outcomes and living donors.
Banaras Hindu University
Dr. Mallika Tewari is Associate Professor & Head for the department of surgical oncology, Banaras Hindu University. Pursuing her career in Clinical academic Surgery she has published more than 100 papers and 7 book chapters. Dr. Tewari have also attended more than 50 conferences.
Koch Institute for Integrative Cancer Research at MIT
Dr. Hu is currently a research scientist in the Koch Institute for Integrative Cancer Research at MIT. His current research focuses on systems biology with 1) high-throughput drug screening on human macrophages for immunotherapy, 2) system biology of lung macrophages and diseases, 3) transcriptional regulation of memory CD8+ T cells. Dr. Hu obtained his PhD at Nanyang Technological University of Singapore in 2009 and then joined in Koch Institute at MIT as postdoc. Prior to his PhD, Guangan awarded his bachelor’s in bioengineering and master’s in molecular cell and biochemistry at Hubei University, China in 2003.
Associate Professor, Associate Director of Graduate Immunology Program Faculty Director of Transgenic and Gene Targeting Facility
University of Pittsburgh School of Medicine
Pittsburgh, United States
Dr. Binfeng Lu is Faculty Director at Transgenic Gene Targeting Core, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. He received his Major in Biology at Tsinghua University, Beijing, China. Dr. Lu received his Ph.D. from Integrated program of cellular, molecular and biophysical studies, Columbia University, New York. Dr. Binfeng Lu has served on many NIH, AHA, AA review panels, has reviewed for many journals. Dr. Binfeng Lu has many peer reviewed publications and is funded by the NIH, VA, NSF and several foundations. Dr. Binfeng Lu research interests include discovery of novel molecular and cellular pathways regulating key steps of T cell-mediated tissue-focused immune responses in antitumor immunity and autoimmunity. Binfeng Lu is having many honors and awards like AAI travel award, overseas outstanding young scientists award, Natural Science Foundation of China, Guest Professor and Ph.D. advisor, Wuhan University, Guest Professor and Ph.D. advisor, Soochow University.
Leandro Bueno Bergantin
Department of Pharmacology
Federal University of São Paulo
Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain): degree in biomedicine (2008), MSc (2010) and PhD (2014). His research involves cell signaling mediated by Ca2+ and cAMP, skeletal and smooth muscles, peripheral and central nervous systems. His research work solved the enigma of the paradoxical effects produced by Ltype Ca2+ channel blockers (TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular Biology - Cell Calcium - TOP 1 July to September 2013/ TOP 5 October to December 2013/ TOP 1 January to December 2013 full year/TOP 6 January to March 2014). Since 1975, several clinical and experimental studies have reported that acute and chronic administration of L-type Ca2+ channel blockers (CCB), such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. Despite this sympathetic hyperactivity has been initially attributed to adjust reflex of arterial pressure, the cellular and molecular mechanisms involved in this apparent sympathomimetic effect of the L-type CCB remained unclear for decades. In 2013, Dr. Bergantin and collaborators discovered that this paradoxical increase in sympathetic activity produced by L-type CCB is due to interaction of the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of the Ca2+/cAMP interaction produced by combination of the L-type CCB used in the antihypertensive therapy, and cAMP accumulating compounds used in the antidepressive therapy, could represent a potential cardiovascular risk for hypertensive patients due to increase in sympathetic activity. In contrast, this pharmacological manipulation could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders and producing neuroprotection in the neurodegenerative diseases (Bergantin and Caricati-Neto, 2016 Eur J Pharmacol; Caricati-Neto et al., 2015 Pharm Res Perspect). Dr. Bergantin has published several articles in international journals, book chapters, and an international book. He is member of editorial board of several international journals.
Hank Schmidt MD PHD
Division of Surgical Oncology
Department of Surgery, Icahn School of Medicine at Mount Sinai
Dubin Breast Center of the Tisch Cancer Institute
Dr Schmidt is a board-certified surgeon specializing in surgical oncology and particularly in care of patients with breast cancer. He is trained in Molecular Medicine and Genetics with post-doctoral experience in cell signaling, cancer biology, and translational research for development of novel targeted therapies. Currently he is director of the Cancer Risk Program at the Dubin Breast Center at Mount Sinai with expertise in management of patients at high risk for breast cancer and other malignancies. Dr Schmidt is a Principal Investigator of the Breast Cancer Biospecimen Repository and as a member of the Tisch Cancer Institute, he is involved in multiple clinical/translational studies aimed at improving outcomes for breast cancer patients.
Bioinformatics and Biostatistics
University of Louisville
Dongfeng Wu is a Member of American Statistical Association (ASA)International Biometric Society-East North American Region (ENAR) Editorial Services Editorial board member, Journal of Biometrics and Biostatistics;Editorial board member, Journal of Modern Applied Statistical Methods.Ad-hoc Member/Reviewer a. National Institute of Health (NIH), Special Emphasis Panel ZRG1 PSE-C (58) and ZRG1 PSE-J (58) R, challenge grant proposals review, May 2009. b. Judge for Research!Louisville, 2008, 2009. c. Educational Testing Service (ETS) AP reader of Statistics, June 5-11, 2009. d. Chaired a session at the Joint Statistical Meeting (JSM)2006, Seattle, WA, and section title: “Spline-based methods.”Referee Statistics in Medicine; Information Sciences; Quality of Life Research; Cancer; Statistical Methodology; Printice Hall; W.H. Freeman and Company. Other Services: At University of Louisville, SPHIS Faculty Forum Committee member, School Academic Affair Committee member, School Curriculum Committee member; Department of Bioinformatics and Biostatistics Master’s Program Director. At Mississippi State University, University Academic Review Board, 2002-03, University of Grievance Panel, 2005-2007, Departmental Statistics Committee, Departmental Computing and Technology Committee, Departmental Assessment Committee, Departmental Evaluation of Teaching Assistants Committee.
Radiology - Nuclear Medicine
Demir Akin Congretionally Directed Medical Research Programs, Breast Cancer Research Program, National Cancer Institute, Alliance for Nanotechnology in Cancer, Radiation Oncology Program, CDMRP/DoD, American Association for Cancer Research (AACR), U.S. Civilian Research and Development Foundation (CRDF).
Dae Joon Kim
Department of Pharmacology
University of Texas
Dae Joon Kim is an Assistant Professor in the Department of Pharmacology, University of Texas, USA. Chair of Chemical Carcinogenesis Poster Session, The 48th Annual Meeting of Society of Toxicology, March 2009. Postdoctoral Representative for Dermal Toxicology Specialty Section, Society of Toxicology, 2008 - 2010. American Association for Cancer Research, 2005 - present. The American Society for Cell Biology, 2003 - present. Society of Toxicology, 2002 - present.
Department of Medical Oncology
The South Western Medical Center
Chulso Moon is having 1. Tenure Track Professorship in the Department of Oncology, Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine (2001-2007). 2. Principal Investigator, The Head and Neck Cancer Research Institute, The Johns Hopkins University School of Medicine (Director: Dr. David Sidransky) (2001-). 3. Attending physician, The Johns Hopkins Hospital (2001-2006). 4. Principal investigator, ONXY-015 cancer genetherapy program for advanced head/neck cancer (2001-2003). 5. Adjunct Professorship, Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University school of Medicine (2008- Present). 6. Preceptor, Graduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University school of Medicine (2005- Present, Thesis Advisor for Juna Lee, 2010 Ph.D. Candidate). 7. Director of Medical Oncology, Cleo Craig Memorial Cancer Clinic, The South-Western Medical Center, Lawton OK (2010-Present).
Department of Oncology, Phase I- Early Clinical Trials Unit
University Hospital Antwerp
Christian Rolfo is part of the working group of the ETOP mesothelioma (European Platform Thoracic Oncology), led by Prof. Rolf Stahel. He is a member of Translational Oncology Multidisciplinary group of university research Institute of Health Sciences (IUNICS) at the University of the Balearic Islands He is member of prestigious Societies Including IASLC, ESMO and ASCO. He was appointed in February 2011 visiting professor in Medical Oncology by the Molecular and Clinical Genetic Oncology Unit at the Interdepartmental Center of Research in Clinical Oncology, School of Medicine, University of Palermo (Italy). In addition to teaching duties at the University of the Balearic Islands. From October 2012 is Senior Staff Member in the Department of Oncology, University Hospital Antwerp, Belgium, headed by Prof. Marc Peeters. Dr. Rolfo works in Phase I - Early Clinical Trials Unit and Development of new drugs, as well as clinical research projects in thoracic tumors and teaching duties at the University of Antwerp. In November 2012 Dr. Rolfo was distinguished with the title of Senior Fellowship of New Westminster College in Vancouver, British Columbia, Canada.
Charles Kumar Thodeti
Integrative Medical Sciences
Northeast Ohio Medical University
Charles Kumar Thodeti is an Assistant Professor of Vascular Biology at Department of Integrative Medical Sciences, NEOUCOM(North Eastern Ohio Universities College of Medicine) Faculty, School of Biomedical Sciences, Kent State University, Ohio. He has received PhD in Zoology (Biochemistry &Physiology) from S.V. University, Tirupati, India, 1994. He has completed his M.S. in Zoology S.V. University, Tirupati, India, 1987. He is serving as an editorial board member of 1 journal and reviewer of 3 journals.
Ardeshir Hakam, MD, MBA
Oncologic Sciences & Pathology
University of South Florida
Ardeshir Hakam is an Associate Professor of Oncology, Pathology and cell biology. Currently, he is Director of Surgical Pathology at Moffitt Cancer Center and research institute and Program Director of Oncologic Surgical Pathology Fellowship at the University of South Florida. Dr. Hakam is a board-certified Pathologist and Cytopathologist. His training includes Anatomic & Clinical Pathology Residency at University of Hawaii, school of Medicine and fellowship trainings in Genitor-urinary pathology at University of Pittsburgh Medical Center and Oncologic Pathology and Cytopathology at University of South Florida, College of Medicine. He has published many peer reviewed articles, and abstracts in national meetings.
National Cancer Institute
Anil Wali is a Program Director in the Diversity Training Branch for the Center to Reduce Cancer Health Disparities. He provides technical and scientific expertise and grants program administration guidance to trainees and early stage investigators. Dr. Wali joined CRCHD in 2009 from Wayne State University, Detroit Medical Center and NCI designated Comprehensive Cancer Center Barbara Ann Karmanos Cancer Institute where he served as Associate Professor in the Departments of Surgery and Pathology. Dr. Wali also served as Principal Investigator on a Veterans Administration Merit Review award funded project on the Role of Ubiquitin-Proteasome Pathway in Mesothelioma Carcinogenesis. Dr. Wali conducted NCI Clinical trial on asbestos exposed patient populations to determine their risk for developing Lung Cancer and Mesothelioma using high throughput Genomics and Proteomics technologies. Dr. Wali received his B.S. and M.S. degrees from the University of Kashmir, in Srinagar, India. He earned his Ph.D. at the Postgraduate Institute in Chandigarh, India. Dr. Wali completed postdoctoral training at the Institute for Environmental Medicine at the University of Pennsylvania at the FELS Institute for Cancer Research at Temple University, Philadelphia, PA and in the Department of Pathology at Thomas Jefferson University, Philadelphia, PA.
Professor of Immunology and Genetics at Dept Genetics, Cell and Immunobiology
Andras Falus (born 1947), PhD, DSc, med. habil. Professor of Immunology and Genetics at Dept Genetics, Cell and Immunobiology, Semmelweis University, Budapest. Professor of Immunology and Sytems Biology of Pazmany Peter Catholic University. Member of Hungarian Academy of Sciences and Academia Europeae. Former President of Hungarian Society of Immunology. Founder of Hungarian Biobanking system. Member of Henry Kunkel Society of Rockefeller University, NY. Founder Editor of Immunome Research, member of Board of Autoimmunity and Cellular Molecular Life Sciences. Co-founder and Chairman of of Eduvital Nonprofit health Education Society.
Department of Molecular Pharmacology and Therapeutics
Ajay Rana is Professor in the Department of Molecular Pharmacology and Therapeutics. He completed his education at Indian Institute of Chemical Biology, Jadavpur University, Calcutta, India.
Professor and Research Director
Department of Developmental Dentistry
The University of Texas Health Science Center at San Antonio
Texas, United States
Department of Pharmaceutical Analysis
Tabriz University of Medical Sciences
Ved Pal Singh
Department of Biochemistry
Innovative College of Pharmacy
Rameshwar NK Bamezai
School of Computational and Integrative Sciences
Jawaharlal Nehru University
New Delhi, India
Carina Alexandra Fernandes Ladeira
Laboratorial Biomedical Sciences
School of Health Technology of Lisbon
Department of Surgery
St George Hospital, The University of New South Wales
Protein and Nucleic Acid Facility
Khandelwal Sharad Ratan
Department of Microbiology
Institute of life sciences, HPT/RYK College, Nashik
Institute of Medical Genetics, Cardiff University
Richard J Simpson
Department of Biochemistry and Molecular Biology
University of Melbourne
Gregory S Yochum
Biochemistry and Molecular Biology
Pennsylvania State University
Chairperson of Department of Eastern Medicine, Directorate of Medical Sciences
Government College University Faisalabad
Rahul S. Shinde
Immunology, Microenvironment and Metastasis program
The Wistar Institute, Philadelphia
We are currently preparing the current issue.
You can submit your manuscript at Science Repository. Authors submit manuscript files and metadata & can request for revision. Editors use the system to review submissions, assign to reviewers, and make and communicate decisions to accept, revise, transfer or reject manuscripts. Reviewers are invited to work on manuscripts, can accept or reject assignments.
For submission authors can directly submit manuscript to firstname.lastname@example.org
Manuscripts number will be provided to the corresponding author within 72 hours for the respective manuscript submitted.
- 14 day review process with international peer-review standards
- Timeline of processing from Submission to Publication is 30 days
- Manuscript will be published within 7 days of acceptance
Carcinogenesis & Mutagenesis Case Reports is an Open Access journal and we do not charge the end user when accessing a manuscript or any article. This allows the scientific community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License".
In line with other open access journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.
The publication charge for Carcinogenesis & Mutagenesis Case Reports is £ (GBP) 1099.
Frequently Asked Questions (FAQs)
Why do we charge?
All articles published in Science Repository are open access. Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in Science Repository Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles and submitting the articles in electronic citation database like CrossRef.
Our financial goals are to:
- Maintain the portal for best experienece
- Recover capitalization cost
- Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development
- Although we charge the minimum possible but we will reduce the publication-charge cost downward over time.
When should I pay?
Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior to submission.
*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.
Who will pay the APC (Article Processing Charges)?
Corresponding author or Co-authors has to make the payment on acceptance of the article.
How do I pay?
Authors or institutions can make payments by two modes as per their convenience.
- Online Card payment
Note: No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction gateway charges may be levied on the payee.
Do I have to pay if my manuscript is rejected?
No, Article processing charges will not be applicable for articles rejected by the Editorial office.
Can I be eligible for wavier on APC?
The waiver request will be considered on a case-by-case basis, and will be provided accordingly.
*The Waiver requests must be made during the submission process and will not be accepted after processing of the manuscript.
Please check our Refund Policy
Are reprints of my article included in the article processing charges (APCs)?
No, Article processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.
We are currently preparing the archive. Will be updated soon.